LuciErda 5mg (Erdafitinib)
| Active Ingredient | Erdafitinib |
|---|---|
| Dosage Form | Tablets |
| Indication | urothelial cancer |
| Packaging | 28 tablets in bottle |
| Strength | 5 mg |
| Manufacturer | Lucius Pharmaceuticals, Laos |
| Country of Origin | Laos |
Description
About LuciErda 5mg
LuciErda 5mg contains the active ingredient Erdafitinib. The medicine is useful for the treatment of adult patients with metastatic urothelial (bladder) carcinoma. These patients may have witnessed the progression of the disease after having overcome platinum chemotherapy. Erdafitinib 5Mg is supportive for the management of Urothelial Cancer.
LuciErda 5mg: Composition and Active Ingredients
Active components: Erdafitinib is the active ingredient of LuciErda 5 mg. It is FGFR (fibroblast growth factor receptor). It is also identified as a tyrosine kinase inhibitor. The composition of the medicine may include inactive ingredients.
Inactive components: Inactive components of Erdafitinib 5Mg include Microcrystalline cellulose, Lactose monohydrate, Colloidal silicon dioxide, Magnesium stearate, Sodium starch glycolate, and certain film-coating agents such as titanium dioxide, hypromellose, and various colorants.
Why Choose LuciErda 5mg?
LuciErda 5 mg, containing Erdafitinib 5Mg is a cancer-targeted therapy. It is considered a very crucial medication for cancer treatments and plays a significant role in advanced urothelial carcinoma, identified as a kind of bladder cancer.
Uses of LuciErda 5 mg
Urothelial Cancer: It is a targeted therapy for bladder cancer. It is a precision target therapy that is responsible for targeting FGR alterations. The medicine is also suitable for a few kinds of tumors – FGFR2 or FGFR3 genetic mutations and fusions.
Oral formulation: Erdafitinib 5Mg is to be taken by mouth, and is an easy and convenient dosing solution, unlike traditional chemo visits backed by frequent hospital visits. Flexibility in dosage is possible. Dose adjustments should be made according to levels of the blood phosphate.
Clinical safety: Used as Balversa, a FDA-approved drug highly suitable and recommended for Urothelial Cancer. Clinical trials of Erdafitinib 5Mg have shown growth in response rates and survival free from cancer progression. Great option for patients with failed platinum-based chemotherapies.
Easy-tolerance: Erdafitinib 5Mg may usually have better tolerance than traditional chemotherapy. Eye problems and other minor side effects of the medicine may be detected early. There are lower risks for certain systemic toxicities that include nausea, bone marrow suspension, etc.
It is not to be used if you do not have cancer with few genetic features. When used correctly, it may be more effective and potent.
How Does LuciErda 5mg Work?
The mechanism of action for LuciErda 5 mg is as follows:
- Works through the inhibition of FGFR1, FGFR2, FGFR3, and FGFR4 receptors.
- Blocks the ATP binding, causing prevention of phosphorylation.
- Causes the pathways promoting growth, including MAPK/ERK and PI3K/AKT, to shut down.
- FGFR Inhibition leads to stopping the uncontrolled growth of cells, through promotion of apoptosis. It causes the tumor to shrink and delay the progression of the disease.
- It is designed to work in specific individuals with FGFR mutations or the ones with fusions. Genetic testing is important right before the start of the therapy and use of the medicine against Urothelial Cancer.
How to take LuciErda 5 mg?
It is important to take a proper dosage of Erdafitinib 5Mg to ensure its maximum safety and efficacy.
Initial dose: Most of the patients are recommended to use a starting dose of 8mg once a day. Dosage may be increased to 9mg.
Route: LuciErda 5mg must be taken orally. It might be used by an individual without or even with their meal.
Intake: Take LuciErda 5mg without chewing, crushing, or splitting the tablet.
Timing: Follow the same time each day to maintain consistency.
Where to Buy LuciErda 5 mg?
LuciErda 5 mg should be purchased from trusted pharmacies as proper medication for cancer treatment is necessary for better outcomes. Reach out to trusted medical suppliers like Medzsupplier that sources best medications from genuine manufacturers only and delivers them at affordable rates to its valued customers. Bulk packages of LuciErda 5mg may be available at discounted rates.
Dosage of LuciErda Tablet
- Dosage of LuciErda 5mg depends on the patient’s blood phosphate levels, tolerance levels, as well as the status of genetic mutation.
- Starting dose may be 8mg – to be taken for 2 weeks, approximately. Dose may be increased to 9mg.
- LD Tablets might be combined to cater to the necessities of the dosage prescribed.
- 9mg should be the maximum dose for a day.
Side Effects
LuciErda 5 mg is an effective and targeted cancer therapy (successfully used against Urothelial Cancer), but it may lead to a few serious and, in a few cases, permanent side effects. Few symptoms can be managed well, and others may require urgent medical intervention.
Common side effects of LuciErda 5mg: Dry mouth, Hyperphosphatemia, Nail disorders, fatigue, diarrhea, inflammation, mouth sores, loss of hair, loss of weight, dry skin, discoloration, peeling, and increased levels of creatinine.
Side effects related to eye: Vision changes and related symptoms are common with the use of LuciErda 5mg. It may cause:
- Central Serous Retinopathy (CSR) – Halos, blurred vision, visual distortion, and dark spots may be common symptoms.
- Eye irritation/dry eyes
- Poor or blurred vision
Monthly eye examinations may be required along with liver, kidney, Blood phosphate levels, and electrolytes tests.
Serious side effects: Severe nail infections, retinal detachment, severe mouth ulcers, painful throat, phosphate complications, Embryo-fetal toxicity, Liver toxicity, etc.
When to see a doctor? Seek medical help in case of sudden changes in vision, severe mouth sores, pain of swallowing, confusion, extreme fatigue, signs of infection, breathing problems, etc.
Risks and Precautions
LuciErda 5 mg may have significant effects on kidneys, eyes, phosphate levels, as well as pregnancy.
Major risks of LuciErda 5mg include:
Eye disorders: Central serous retinopathy (CSR) and retinal detachment in patients are possible. Symptoms may be visual distortion, blurred vision, dark spots, and halos. Monthly eye examinations are important.
Hyperphosphatemia (indicated by a High Blood Phosphate): Use of Erdafitinib 5Mg can cause imbalance of calcium-phosphate levels, vascular calcification, and potential damage to the kidney. Serum phosphate levels must be monitored in the first 3 weeks of its use. Dose adjustments may be done when required.
Fetal toxicity: Erdafitinib 5Mg may cause harm to an unborn baby. It may be avoided at the time of pregnancy.
Kidney and liver: Risks of Elevated liver enzymes or stress on kidneys. In case of toxicity, regular monitoring of the condition, dose adjustment, and reduction or pausing of dose may be needed.
Drug interactions: Possible risks of interaction with CYP2C9 and CYP3A4 inhibitors. Grapefruit juice and use of other drugs such as phenytoin, rifampin, and ketoconazole may be avoided.
Skin and nail disorders: Risks of loss of nails, infection, and painful detachment can be expected. Make sure to report all possible signs of nail infection and maintain proper hygiene.
Conclusion
Patients may need regular blood tests, genetic testing, eye examinations, and careful monitoring of liver and renal disease when they are using LuciErda 5 mg.
Treatment may be stopped or modified in case of visual changes, mouth sores, and severe side effects even after dose reduction/adjustment.
Reviews
There are no reviews yet.